The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Brought to you by Scientific Education Support

The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Create an account and access these new features:

Bookmark content to read later

Select your specific areas of interest

View all content recommended for you

EHA 2024 abstracts: What’s hot in ALL?

By Abhilasha Verma,Quintina Dawson

Featured:

Hervé Dombret

Charles Mullighan

Franco Locatelli Emmanuelle Clappier

Jun 7, 2024

Learning objective: After reading this article, learners will be able to cite a new clinical development in ALL.

To help navigate the exciting content being presented at the European Hematology Association (EHA) 2024 Hybrid Congress, the ALL Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in ALL.

Frontline and emerging therapies for ALL

S111	Blinatumomab for first line treatment in intermediate and high risk Down Syndrome B-cell acute lymphoblastic leukaemia: Initial findings from the ALLTOGETHER1 DS TRIAL
S112	Blinatumomab as consolidation in a paediatric protocol leads to high rates of end-consolidation MRD negativity and excellent outcomes in AYA ALL – Final results of the ALLG ALL09 "SUBLIME" STUDY
S113	Blinatumomab added to prephase and consolidation therapy in adult B-ALL: A comparison of the consecutive HOVON-100 AND H-146 studies
S115	Ponatinib versus imatinib in patients with newly diagnosed Ph+ acute lymphoblastic leukemia in the phase 3 PHALLCON trial: In depth responder analysis
P397	Augmented use of L-asparaginase markedly improves the treatment result of AYA ALL patients: Result of prospective MRD 2014 study conducted by Fukuoka Blood And Marrow Transplantation Group (FBMTG)
P398	Ponatinib, chemotherapy and transplantation for newly diagnosed adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Final results of the phase 2 PONALFIL trial
P400	Busulfan plus cyclophosphamide vs. Total body irradiation plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in patients with acute T lymphoblastic leukemia
P407	Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL): Post hoc analysis of adverse events of interest from AALL1931
P409	Blinatumomab induction therapy following reduced-dose chemotherapy in newly diagnosed adult Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia: Multicentre, single arm, phase 2 study
P411	A full pediatric regimen for adult patients with Philadelphia negative acute lymphoblastic leukemia achieves excellent outcomes with acceptable toxicity
P416	Blinatumomab alternating with low-intensity chemotherapy (LIC) in older adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL): Safety run-in follow-up for the phase 3 GOLDEN GATE study.
P427	Combination of third generation TKI olverembatinib and chemotherapy or blinatumomab for new diagnosed adult Ph+ ALL patients
P1740	Improving outcome in elderly Philadelphia negative acute lymphoblastic leukemia: Feasibility and efficacy of an intensive PEG-asparaginase-based regimen

Treatments for relapsed/refractory ALL

S110	WU-CART-007, an allogeneic CAR-T cell targeting CD7, is highly effective against relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL)
S114	Obecabtagene autoleucel in adult relapsed/refractory B-cell acute lymphoblastic leukemia: Survival and potential impact of CAR T-cell persistence and stem cell transplantation in the FELIX Study
P395	Subsequent allotransplant in adults with advanced acute lymphoblastic leukemia after CD19 CAR T-cell therapy: A multi-center randomized controlled trial
P402	Efficacy and tolerance of modified HyperCVAD, blinatumomab, and TKI, combination as a treatment for relapsed or refractory Ph+ B-cell acute lymphoblastic leukemia
P429	Five-year outcome of CD19 combined with CD22 CAR T-cell therapy in B-ALL patients relapsed after allo-transplantation

Biomarkers, prognosis, and biology

S116	Early response refines end of induction measurable residual disease stratification in T-cell acute lymphoblastic leukaemia
P403	MRD monitoring in childhood Ph-positive acute lymphoblastic leukemia: Prognostic significance and correlation between multiparameter flow cytometry and RT-QPCR
P419	Impact of NGS MRD and clonal evolution on clinical prognosis in pediatric Ph+ ALL patients
P368	The genomic landscape of relapsed infant and childhood KNT2A-rearranged acute leukemia

Real-world outcomes

P413	Brexucabtagene autoleucel (Brexu-cel) as consolidation treatment in adults with B-cell acute lymphoblastic leukemia with marrow blasts <5%, including patients (pts) with NGS MRD negative disease
P424	Real-world utilization of blinatumomab in adult and pediatric patients with acute lymphoblastic leukemia in France: Results from the ATHENA study

EHA24 Top Abstracts

To download this document, click below.

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EHA 2024

Subscribe to get the best content delivered to your inbox

EHA 2024 abstracts: What’s hot in ALL?

Frontline and emerging therapies for ALL

Treatments for relapsed/refractory ALL

Biomarkers, prognosis, and biology

Real-world outcomes

Newsletter

Areas of interest